Nov 4, 4:31 PM ET
Phibro Animal Health reported higher first-quarter results for the period ended September 30, 2026, with net sales up 6% and net income up 11% from a year earlier. The company kept its fiscal 2027 guidance unchanged, and stockholders re-elected three Class I directors and ratified PricewaterhouseCoopers as auditor at the November 3, 2026 annual meeting.
- Net sales of $386.8 million rose $22.9 million, or 6%, led by Mineral Nutrition, which rose 17%.
- Net income of $29.5 million rose 11%, and diluted EPS of $0.72 rose $0.07 from $0.65.
- Fiscal 2027 guidance was maintained: net sales of $1.55 billion to $1.60 billion and adjusted EBITDA of $258 million to $268 million.
- At the November 3, 2026 annual meeting, all three director nominees were elected and PwC was ratified for the fiscal year ending June 30, 2027.
Read the filing on SEC.gov ↗
Nov 3, 4:15 PM ET
Phibro Animal Health's board declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. Holders of record at the close of business on November 25, 2026 will receive the payment on December 16, 2026.
- Quarterly cash dividend of $0.12 per share on Class A and Class B common stock
- Record date: November 25, 2026
- Payment date: December 16, 2026
Read the filing on SEC.gov ↗
Aug 26, 4:30 PM ET
Phibro Animal Health reported results for the fiscal year ended June 30, 2026, with net sales up 17% to $1.52 billion and net income up to $99.7 million from $48.3 million. It also gave fiscal 2027 guidance for net sales of $1.55 billion to $1.60 billion and adjusted diluted EPS of $3.41 to $3.59, and said it will close its Chicago Heights, Illinois plant, affecting about 100 employees.
- Fiscal 2026 diluted EPS was $2.43, up $1.24, and adjusted EBITDA was $255.0 million, up 39%.
- Fourth-quarter net sales were $396.7 million, up 5%, and net income was $21.7 million, up 26%.
- Fiscal 2027 guidance: net income of $122 million to $132 million and adjusted EBITDA of $258 million to $268 million.
- Chicago Heights production is expected to cease during the summer of 2027, with products moved to other Phibro facilities and third-party contract manufacturers.
Read the filing on SEC.gov ↗
Jun 26, 5:07 PM ET
Phibro Animal Health said Daniel (Dani) Bendheim will become Chief Executive Officer and President effective July 1, 2026, under a new employment agreement with a $850,000 base salary. He also received a grant of 300,000 performance-based restricted stock units that vest only if the company's 90-day average stock price reaches $70 to $100 by June 30, 2031.
- Bendheim's base salary is $850,000 annually, with a target bonus of 50% of base salary.
- The 300,000 RSUs vest in 25% increments tied to a 90-day average stock price from $70 to $100 or above, with no vesting below $70.
- Severance includes six months of base salary on death or disability and up to 18 months of company-subsidized COBRA coverage on termination without Cause or resignation.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.